89bio Ltd.   Report issue

For profit Phase 2 Phase 3
Founded: San Francisco CA United States (2018)

Organization Overview

First Clinical Trial
2019
NCT04048135
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

89bio, Inc. | 89bio Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

pegozafermin (1 trial)

Drugs in Phase 2 Trials (1)

bio89-100 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatty Liver (Phase 2)

Hypertriglyceridemia (Phase 2)

Liver Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 2